A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

Conditions:   Breast Neoplasms;   Breast Diseases;   Capecitabine;   HER2-positive Breast Cancer;   HER2 Positive Breast Carcinoma Interventions:   Drug: RC48-ADC;   Drug: Lapatinib;   Drug: Capecitabine Sponsor:   RemeGen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials